MARTINSRIED / MUNCHEN, GERMANY--(Marketwired - May 13, 2013) -
MorphoSys AG /
MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today
has dosed the first patient in a Phase 2 clinical trial of MOR208 in
Hodgkin's Lymphoma (NHL). MOR208 is a potent Fc-optimized anti-CD19
which MorphoSys gained worldwide rights via an exclusive license
collaboration agreement with Xencor in 2010.
The open-label, multicenter, single-arm clinical trial is designed to
efficacy of MOR208 in patients with relapsed or refractory Non-
Lymphoma. Secondary outcome measures include response duration,
pharmacokinetics of MOR208. A total of up to 120 patients are planned
enrolled in four separate sub-indications (FL, MCL, DLBCL and other
indolent NHL). More information on the trial can be found by
MOR208 at www.clinicaltrials.gov. The trial is to be conducted at sites
both Europe and the US.
"In MOR208 we have a very exciting cancer program with a huge
Evaluating MOR208 in NHL and B-ALL - building on the data we already
CLL - should enable us to assess the therapeutic benefit and broader
potential of the molecule in hematological malignancies," commented Dr.
Schottelius, Chief Development Officer of MorphoSys AG. "Broadening the
development program into additional indications is intended to
value of this compound."
MOR208 showed encouraging signs of preliminary anti-tumor activity
acceptable safety and tolerability profile in a Phase 1/2a trial in
with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or
lymphocytic lymphoma (SLL). In addition to the phase 2 trial in NHL,
is currently evaluating the compound in a phase 2 trial in B-cell
Lymphoblastic Leukemia (B-ALL).
B-cell malignancies, such as B-ALL, NHL and CLL affect more than one
fifty thousand patients in the seven major markets each year. The
molecule CD19 is expressed more broadly and earlier in B-cell development
CD20, the target of the marketed cancer drug Rituxan®. Therefore
CD19 could potentially allow for an even broader therapeutic use of MOR208
marketed anti-CD20 antibodies.
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®,
Ylanthia® and 100 billion high potentials® are registered
Slonomics® is a registered trademark of Sloning BioTechnology
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
Media Release (PDF):